Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids
Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids
Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids
Summary of opinion: Tagrisso, 14/11/2024 Positive
Summary of opinion: Rybrevant, 14/11/2024 Positive
EMA encourages companies to submit type I variations for 2024 by end November 2024
Expert reports on big data related topics
Social Media Data for Real World Evidence in Regulatory Decision Making
Article 57 product data
EMEA-003474-PIP01-23
EMEA-003482-PIP01-23
Opinion/decision on a Paediatric investigation plan (PIP): Tezspire, tezepelumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Gastroentology-Hepatology, PIP number: P/0407/2023